Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Trial Investigating the Safety, Tolerability and Efficacy of EXT608 in Adults With Hypoparathyroidism

NCT06988670 is registered in ClinicalTrials.gov with Extend Biosciences Inc. as lead sponsor.

NCT NCT06988670
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06988670 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Trial Investigating the Safety, Tolerability and Efficacy of EXT608 in Adults With Hypoparathyroidism
Lead sponsor
Extend Biosciences Inc.
Phase
Phase 2
Overall status
Recruiting
Start date
May 5, 2025
Completion date
May 31, 2027
Enrollment
35 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hypoparathyroidism